NEW YORK--(BUSINESS WIRE)--Saghmos Therapeutics, Inc., a privately held biopharmaceutical company whose mission is to prevent and treat kidney injury due to contrast dyes, today announced that it will present at the 20th Annual BIO CEO & Investor conference.
Anna Kazanchyan, M.D., Chief Executive Officer and Chairwoman of Saghmos, will provide an overview of Saghmos and its lead program, ST-62516, which is positioned to enter Phase 3 development to improve cardiorenal outcomes in patients undergoing percutaneous coronary intervention (PCI). The presentation is scheduled for February 12, 2018 at 3:45 pm in the Brecht Room at the New York Marriott Marquis.
BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging biotech companies. BIO CEO provides a forum for institutional investors, industry analysts and senior biotechnology executives to shape the future of the biotechnology industry.
About Saghmos Therapeutics
Saghmos Therapeutics is a privately held biopharmaceutical company whose mission is to prevent and treat kidney injury due to contrast dyes. Saghmos’ lead program, ST-62516 is positioned to enter Phase 3 development for reduction of major adverse renal and cardiac events (MARCE) associated with contrast-induced acute kidney injury (CI-AKI) in patients undergoing percutaneous coronary intervention (PCI). CI-AKI is a silent killer, leading to heart attacks, prolonged hospitalization, need for dialysis and death. It is a multi-billion dollar market opportunity, with no FDA-approved drugs for prevention or treatment.